Risk of development discontinuation due to deaths and serious adverse reactions for which a causal relationship to CTX-712 administration cannot be ruled out
First written in FY2024. 1 of 3 entries say "Materialised", first in FY2024. Latest entry: 2026-10-15.
Chordia Therapeutics moved to the "Worse" side of this theme in 2024, 1 year before the typical company in this theme (2025).
The whole theme swung hardest in 2026: 6 of 20 companies on the "Worse" side.
9 other companies' latest entry also says "Mitigated".
- 2026-10-15MitigatedPresentation materials on financial results
「主な副作用は消化器症状が中心で血液毒性は限定的であり、管理可能な安全性プロファイルを確認」
米国第1/2相試験の42症例について、主な副作用と安全性プロファイルが示され、管理可能との評価が記載された。既存の国内試験に関するリスク記載を変更するものではない。 - FY2025WorsenedAnnual report
「In the clinical trial, 3 deaths occurred for which a causal relationship with administration of rogocekib cannot be ruled out. All cases were reported to the regulatory authorities, and the trial is continuing following amendment of the clinical trial protocol to enable the trial to be conducted more safely. We currently believe that development of this pipeline can continue; however, if serious adverse reactions, particularly deaths, continue and the risk of serious adverse reactions cannot be reduced, development of this pipeline may be discontinued.」
Deaths for which a causal relationship with rogocekib administration cannot be ruled out increased from the 2 previously disclosed cases to 3. The trial is continuing after amendment of the clinical trial protocol, but the possibility of discontinuing development was disclosed. - FY2024MaterialisedAnnual report
「In the Phase 1 clinical trial in Japan, 2 deaths occurred for which a causal relationship with administration of CTX-712 cannot be ruled out.」
In Japan's Phase 1 trial of CTX-712, 2 deaths occurred for which a causal relationship with administration cannot be ruled out. The trial is continuing after amendment of the clinical trial protocol, but the possibility of discontinuing development if serious adverse reactions persist has been disclosed.